Vaccine (DNA plasmid) · Immune activation · developed by INOVIO PHARMACEUTICALS
Rocakinogene sifuplasmid is a plasmid DNA vaccine encoding human interleukin-12 delivered by intramuscular or intradermal electroporation. It activates the immune system by promoting NK cell activation, interferon-gamma secretion, and cytotoxic T-cell responses against tumor cells. It is studied in hepatocellular carcinoma, glioblastoma, chronic hepatitis C, and Ebola infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03491683 | Phase 1/2 | Glioblastoma | Active not recruiting | INO |
| NCT02772003 | Phase 1 | Chronic Hepatitis | Active not recruiting | INO |
| NCT02464670 | Phase 1 | Ebola Vaccine | Completed | INO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic HepatitisGlioblastomaHepatitis C InfectionHepatocellular CarcinomaEbola Vaccine
Updated Oct 3, 2026. Something wrong or missing? Report it on the INO page.
See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INO catalysts and pipeline →